1
|
Pignatti E, Maccaferri M, Pisciotta A, Carnevale G, Salvarani C. A comprehensive review on the role of mesenchymal stromal/stem cells in the management of rheumatoid arthritis. Expert Rev Clin Immunol 2024; 20:463-484. [PMID: 38163928 DOI: 10.1080/1744666x.2023.2299729] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2023] [Accepted: 12/21/2023] [Indexed: 01/03/2024]
Abstract
INTRODUCTION Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory disease with systemic manifestations. Although the success of immune modulatory drug therapy is considerable, about 40% of patients do not respond to treatment. Mesenchymal stromal/stem cells (MSCs) have been demonstrated to have therapeutic potential for inflammatory diseases. AREAS COVERED This review provides an update on RA disease and on pre-clinical and clinical studies using MSCs from bone marrow, umbilical cord, adipose tissue, and dental pulp, to regulate the immune response. Moreover, the clinical use, safety, limitations, and future perspective of MSCs in RA are discussed. Using the PubMed database and ClincalTrials.gov, peer-reviewed full-text papers, abstracts and clinical trials were identified from 1985 through to April 2023. EXPERT OPINION MSCs demonstrated a satisfactory safety profile and potential for clinical efficacy. However, it is mandatory to deepen the investigations on how MSCs affect the proinflammatory deregulated RA patients' cells. MSCs are potentially good candidates for severe RA patients not responding to conventional therapies but a long-term follow-up after stem cells treatment and standardized protocols are needed. Future research should focus on well-designed multicenter randomized clinical trials with adequate sample sizes and properly selected patients satisfying RA criteria for a valid efficacy evaluation.
Collapse
Affiliation(s)
- Elisa Pignatti
- Department of Surgery, Medicine Dentistry and Morphological Sciences with Interest in Transplant, Oncological and Regenerative Medicine, University of Modena and Reggio Emilia, Modena, Italy
| | - Monia Maccaferri
- Department of Surgery, Medicine Dentistry and Morphological Sciences with Interest in Transplant, Oncological and Regenerative Medicine, University of Modena and Reggio Emilia, Modena, Italy
| | - Alessandra Pisciotta
- Department of Surgery, Medicine Dentistry and Morphological Sciences with Interest in Transplant, Oncological and Regenerative Medicine, University of Modena and Reggio Emilia, Modena, Italy
| | - Gianluca Carnevale
- Department of Surgery, Medicine Dentistry and Morphological Sciences with Interest in Transplant, Oncological and Regenerative Medicine, University of Modena and Reggio Emilia, Modena, Italy
| | - Carlo Salvarani
- Department of Surgery, Medicine Dentistry and Morphological Sciences with Interest in Transplant, Oncological and Regenerative Medicine, University of Modena and Reggio Emilia, Modena, Italy
- Rheumatology Unit, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy
| |
Collapse
|
2
|
Chen P, Lin Y, Lin W, Li Y, Fu T, Liu Y, Guan T, Xin M, Ye L, Wang P, Zeng H, Yao K. Human dental pulp stem cells have comparable abilities to umbilical cord mesenchymal stem/stromal cells in regulating inflammation and ameliorating hepatic fibrosis. Hum Cell 2024; 37:204-213. [PMID: 37964155 DOI: 10.1007/s13577-023-01004-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2023] [Accepted: 10/25/2023] [Indexed: 11/16/2023]
Abstract
Hepatic fibrosis, also called cirrhosis, have wide prevalence worldwide for long yeas. Recently, many treatments for liver cirrhosis made marked progress, especially the umbilical cord-derived mesenchymal stromal cells (UCMSC) therapy. However, limited recourses and potential immune-related issues become the obstacles on UCMSC popularization in clinic. Therefore, we took dental pulp stem cells (DPSCs) into the consideration, since autologous DPSCs can be easily obtained without any ethnic or immune-related issues that heterogenous UCMSCs could encounter. We systematically compared the effects of both cell types and found that DPSCs had similar results to UCMSCs in regulating inflammation and reversing hepatic fibrosis. In our study, co-culturing T cells and PBMSCs showed that DPSCs have the ability to inhibit the proliferation of inflammatory cells and downregulate relevant inflammatory factors. In vitro and in vivo sterility tests confirmed the bio-safety of DPSCs. Moreover, the 1 year-aged mouse model demonstrated that DPSCs successfully reversed hepatic fibrosis. Overall, DPSCs demonstrated comparable effectiveness to UCMSCs in regulating inflammation and reversing hepatic fibrosis, particularly in the aged mouse model that represents middle-aged and elderly humans. Since autologous DPSCs avoid potential immune-related issues that heterogenous UCMSCs could encounter, they may be a better choice for stem cell-related therapies.
Collapse
Affiliation(s)
- Peixing Chen
- Department of Oncology, The Second Affiliated Hospital of Shantou University Medical College, Shantou, 515000, Guangdong, China
| | - Yanchun Lin
- Department of Stem Cell Research Center, Guangdong Procapzoom Biosciences, Inc., 11 Guangpuzhong Rd., Guangzhou, 510000, Guangdong, China
| | - Wenbo Lin
- Department of Oncology, The Second Affiliated Hospital of Shantou University Medical College, Shantou, 515000, Guangdong, China
| | - Yun Li
- Department of Stem Cell Research Center, Guangdong Procapzoom Biosciences, Inc., 11 Guangpuzhong Rd., Guangzhou, 510000, Guangdong, China
| | - Ting Fu
- Department of Stem Cell Research Center, Guangdong Procapzoom Biosciences, Inc., 11 Guangpuzhong Rd., Guangzhou, 510000, Guangdong, China
| | - Yuanyue Liu
- Department of Stem Cell Research Center, Guangdong Procapzoom Biosciences, Inc., 11 Guangpuzhong Rd., Guangzhou, 510000, Guangdong, China
| | - Tian Guan
- Department of Stem Cell Research Center, Guangdong Procapzoom Biosciences, Inc., 11 Guangpuzhong Rd., Guangzhou, 510000, Guangdong, China
| | - Man Xin
- Department of Stem Cell Research Center, Guangdong Procapzoom Biosciences, Inc., 11 Guangpuzhong Rd., Guangzhou, 510000, Guangdong, China
| | - Ling Ye
- Department of Stem Cell Research Center, Guangdong Procapzoom Biosciences, Inc., 11 Guangpuzhong Rd., Guangzhou, 510000, Guangdong, China
| | - Peiluan Wang
- Department of Stem Cell Research Center, Guangdong Procapzoom Biosciences, Inc., 11 Guangpuzhong Rd., Guangzhou, 510000, Guangdong, China
| | - Haoyu Zeng
- Department of Stem Cell Research Center, Guangdong Procapzoom Biosciences, Inc., 11 Guangpuzhong Rd., Guangzhou, 510000, Guangdong, China.
| | - Kaitao Yao
- Department of Oncology, The Second Affiliated Hospital of Shantou University Medical College, Shantou, 515000, Guangdong, China.
| |
Collapse
|